{"id":"W2970412630","doi":"10.1053/j.ajkd.2019.06.009","title":"Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency","year":2019,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Relypsa; Sanofi Genzyme; National Institutes of Health; Siemens; Novo Nordisk; Servier; Kyowa Hakko Kirin; Ipsen; Astellas Pharma Canada; Ironwood Pharmaceuticals, Incorporated; Alexion Pharmaceuticals; Boehringer Ingelheim; Gilead Sciences; Novartis; AbbVie; Merck; Tufts Medical Center; Bayer; AstraZeneca","keywords":"Medicine; Renal function; Kidney disease; Albuminuria; Clinical trial; Observational study; Hazard ratio; Creatinine; Internal medicine; Intensive care medicine; Surrogate endpoint; Urology; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2734478,0.002370517,0.005469926,0.002652086,0.001862046,0.009666331,0.005004953,0.01677683,0.004431278],"category_scores_gemma":[0.1422565,0.001812367,0.005832762,0.002147072,0.002153091,0.00483831,0.006234121,0.02626043,0.001382683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008952158,"about_ca_system_score_gemma":0.02052877,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004560653,"about_ca_topic_score_gemma":0.008531782,"domain_scores_codex":[0.9349103,0.04454456,0.008092119,0.002617454,0.007796775,0.002038724],"domain_scores_gemma":[0.772944,0.1488277,0.01596148,0.003441855,0.03721267,0.02161223],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.01092164,0.001340755,0.002359848,0.006971938,0.001758457,0.0003220954,0.001003332,0.001936615,0.002990205,0.006475041,0.7209701,0.24295],"study_design_scores_gemma":[0.01806038,0.004804797,0.025286,0.02761665,0.003605019,0.0004858776,0.001685843,0.006419695,0.00345639,0.02218161,0.8858462,0.0005516618],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.005381645,0.1251698,0.01117117,0.7897798,0.05363133,0.006363689,0.002628221,0.0001751377,0.005699329],"genre_scores_gemma":[0.0867708,0.1654856,0.1034748,0.475513,0.1169632,0.0211716,0.006191212,0.0005167801,0.02391289],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.7265521,"threshold_uncertainty_score":0.8959682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04026963815954018,"score_gpt":0.3754556381424535,"score_spread":0.3351859999829133,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}